HC Wainwright has raised its price target on BioXcel Therapeutics (NASDAQ:BTAI) to $73.00.
According to a report on Tuesday by The Fly, HC Wainwright lowered its price objective for BioXcel Therapeutics (NASDAQ: BTAI), ...
Tag: BTAI, Analyst Rating
Brokerages have issued a consensus recommendation of “Moderate Buy” on BioXcel Therapeutics, Inc. (NASDAQ:BTAI).
According to Bloomberg, the nine brokerages currently covering BioXcel Therapeutics, Inc. (NASDAQ: BTAI) have given the stock's shares an average ...
The CEO of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) sells $583,200.00 in stock.
Vimal Mehta, the Chief Executive Officer of BioXcel Therapeutics, Inc. (NASDAQ: BTAI), sold 30,000 shares of the company's stock on ...
Mizuho has raised its price target on BioXcel Therapeutics (NASDAQ:BTAI) to $24.00.
In a research note distributed to investors on Thursday, analysts from Mizuho raised their target price for BioXcel Therapeutics (NASDAQ: ...
BioXcel Therapeutics (NASDAQ:BTAI) Shares Gap Up Following Analyst Upgrade
Before the market opened on Thursday, the share price of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) increased significantly. This was because ...
Brokerages Consensus Recommendation of “Moderate Buy” for BioXcel Therapeutics, Inc. (NASDAQ:BTAI)
According to Bloomberg.com, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has received an average "Moderate Buy" rating from the nine research firms ...
Brokerages have issued a consensus recommendation of “Moderate Buy” on BioXcel Therapeutics, Inc. (NASDAQ:BTAI).
According to Bloomberg Ratings, the eight analysts following BioXcel Therapeutics, Inc. (NASDAQ: BTAI) have an average "Moderate buy" recommendation for ...
